LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

UroGen Pharma Ltd

Geschlossen

7.34 44.2

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

5.09

Max

8.18

Schlüsselkennzahlen

By Trading Economics

Einkommen

-6.3M

-44M

Verkäufe

-4.3M

20M

EPS

-0.92

Gewinnspanne

-216.466

Angestellte

234

EBITDA

-6.2M

-37M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+295.53% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

12. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-296M

223M

Vorheriger Eröffnungskurs

-36.86

Vorheriger Schlusskurs

7.34

Technischer Score

By Trading Central

Vertrauen

Very Strong Bullish Evidence

UroGen Pharma Ltd Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

16. Mai 2025, 19:39 UTC

Wichtige Markttreiber

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

Peer-Vergleich

Kursveränderung

UroGen Pharma Ltd Prognose

Kursziel

By TipRanks

295.53% Vorteil

12-Monats-Prognose

Durchschnitt 20.33 USD  295.53%

Hoch 36 USD

Tief 3 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für UroGen Pharma Ltd – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

7 ratings

5

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

9.625 / 11.64Unterstützung & Widerstand

Kurzfristig

Very Strong Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Neutral Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über UroGen Pharma Ltd

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.